Mínguez I

Language: Spanish
References: 23
Page: 369-374
PDF size: 60.17 Kb.

ABSTRACT

There is a close, continuous and gradual relationship between cholesterol linked to low density lipoproteins (LDL-c) and coronary disease. For this reason, experts advise a maximum level of 100 mg/dL as a target in secondary prevention. Several megaessays confirm an important decrease of the cardiovascular morbimortality, with statins, regardless the age. Diverse multicentric essays have been accomplished in Spain without showing differences with other countries in Europe and the United States as for the number of treated patients and those patients who reach the ATP III target. Other essays do not show major benefit since the LDL-c is still decreasing below 125 mg/dL. This suggests that the great benefit is reached using statins in figures above the mentioned target, probably for the pleitotropic actions of these medicines. In order to determine the optimum level of LDL-c it is necessary to evaluate the absolute risk of the patient. Here we are treating with patients, not with LDL-c levels. The cholesterol joined to high density lipoproteins firmly reappears as a marking prognosis. It is necessary to use statins in patients with high risk, regardless the LDL-c levels.

REFERENCES

1. National Cholesterol Education Program (NCEP). Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001; 285: 2486-2497.

2. European Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J 2003; 24: 1601-1610.

3. Plaza I, Villar F, Mata P, Perez F, Maiquez A y cols: Control de la colesterolemia en España 2000. Un instrumento para la prevención cardiovascular. Ministerio de Sanidad y Consumo. Sociedad Española de Cardiología. Sociedad Española de Arterioesclerosis. Rev Esp Cardiol 2000; 53(6): 815-837.

4. Pekkanen J, Linn S, Heiss G, et al: Ten-year mortality from cardiovascular disease in relation to cholesterol level among men with and without preexisting cardiovascular disease. N Engl J Med 1990; 322: 1.700-1.707.

5. Grundy SM: HMG-Co-. A reductase inhibitors for treatment of hypercholesterolemia. N Engl J Med 1988; 319: 24-33.

6. The Scandinavian Simvastatin Survival Study Group (4S): Randomized trial of cholesterol lowering in 4,444 patients with coronary heart disease. Lancet 1994; 344: 1383-1389.

7. Sacks FM, Pfeffer MA, Moye LA, et al: The effect of Pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. CARE. N Engl J Med 1996; 335: 1001-1009.

8. The long term intervention with pravastatin in ischaemic disease. LIPID. N Engl J Med 1998: 339: 1349-1357.

9. Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomized placebo controlled trial. HPS. Lancet 2002; 360: 7-22.

10. Shepherd J, Blauw GJ, Murphy MB, et al: Pravastatin in elderly individuals at risk of vascular disease. (PROSPER). Lancet 2002; 360: 1623-1630.

11. Fuster V, Badimón L, Badimón JJ, Chesebro JH: The pathogenesis of coronary artery disease and the acute coronary syndromes (1). N Engl J Med 1992; 326: 242-250.

12. Fuster V, Badimón L, Badimón JJ, Chesebro JH: The pathogenesis of coronary artery disease and the acute coronary syndromes (2). N Engl J Med 1992; 326: 310-318.

13. Di Napoli P, Taccardi AA, Oliver M, De Caterina R: Statins and stroke: evidence for cholesterol-independent effects. Eur Heart J 2002; 23: 1908-1921.

14. Lifestyle and risk factors management and use of drugs therapies in coronary patients from 15 countries. Euroaspire II Group. Eur Heart J 2001; 22: 554-572.

15. Gomez GJA: Jornada de análisis de las dislipemias en España. Clin Drug Invest 2000; 19: 131-142.

16. Serrano PJ, Luengo E, Vegazo O, Banegas JR y cols: Estudio HISPALIPID. Control de la dislipemia en pacientes atendidos ambulatoriamente en el Sistema Sanitario español. Rev Esp Cardiol 2003; 56(Suppl. 2): 162.

17. Barrios V, Ruilope LM, Llisterri JL, Álvarez-Sala JL y cols: Prevención de la enfermedad cardiovascular. Estudio PREVENCAT. Rev Esp Cardiol 2003; 56(Suppl. 2): 25.

18. Serrano PJ, Luengo E, Velasco JA y cols: Lípidos y Prevención Secundaria del Infarto de miocardio en España. Estudio CARDIOLIPID. Rev Esp Cardiol 2003; 56(Suppl. 2): 77.

19. Cullen P, Assmmann G: Treatment goals for lowdensity lipoprotein cholesterol in the secondary prevention of heart disease: absolute levels or extent of lowering? Amer J Cardiol 1997; 80: 1287-1294.

20. Posadas C: Beneficios de la reducción intensiva del colesterol de las lipoproteínas de baja densidad. Arch Cardiol Mex 2003; 73(Suppl. 1): S116-S120.

21. Sirtori CR, Calabresi L, Franceschini G, et al: Cardiovascular status of carriers of the apolipoprotein A-1 (Milano) mutants: The Limone Sul Garda Study. Circulation 2001; 103: 1949-1954.

22. Nissen SE, Tsunoda T, Murat Tuzcu E, Schoenhagen P, Cooper ChJ, Yasín M, Eaton G, et al: Effect of recombinant APO A-1 MILANO on coronary atherosclerosis in patients with acute coronary syndromes. A randomized controlled trial. JAMA 2003; 290: 2292-2300.

23. De Grooth GJ, Kuivenhoven JA, Stalenhoef AF, et al: Efficacy and safety of a novel cholesterol ester transfer protein inhibitor, ITT-705, in humans. A randomized phase II dose response study. Circulation 2002; 105: 2159-2165.